Charles Schwab Investment Management Inc Immunovant, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 442,084 shares of IMVT stock, worth $12.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
442,084
Previous 437,080
1.14%
Holding current value
$12.2 Million
Previous $18.4 Million
22.43%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding IMVT
# of Institutions
238Shares Held
62.9MCall Options Held
1.46MPut Options Held
546K-
Vanguard Group Inc Valley Forge, PA6.48MShares$178 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.48MShares$123 Million0.0% of portfolio
-
State Street Corp Boston, MA3.64MShares$100 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.96MShares$81.5 Million2.01% of portfolio
-
Armistice Capital, LLC New York, NY2.16MShares$59.5 Million0.95% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...